The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.

Détails

Ressource 1Télécharger: 23979955_BIB_C6D390AFE67D.pdf (653.12 [Ko])
Etat: Serval
Version: Final published version
ID Serval
serval:BIB_C6D390AFE67D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.
Périodique
Journal of Clinical Endocrinology and Metabolism
Auteur(s)
Bone H.G., Chapurlat R., Brandi M.L., Brown J.P., Czerwinski E., Krieg M.A., Mellström D., Radominski S.C., Reginster J.Y., Resch H., Ivorra J.A., Roux C., Vittinghoff E., Daizadeh N.S., Wang A., Bradley M.N., Franchimont N., Geller M.L., Wagman R.B., Cummings S.R., Papapoulos S.
ISSN
1945-7197 (Electronic)
ISSN-L
0021-972X
Statut éditorial
Publié
Date de publication
2013
Volume
98
Numéro
11
Pages
4483-4492
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
CONTEXT: The Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) extension is evaluating the long-term efficacy and safety of denosumab for up to 10 years.
OBJECTIVE: The objective of the study was to report results from the first 3 years of the extension, representing up to 6 years of denosumab exposure.
DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, international, open-label study of 4550 women.
INTERVENTION: Women from the FREEDOM denosumab group received 3 more years of denosumab for a total of 6 years (long-term) and women from the FREEDOM placebo group received 3 years of denosumab (crossover).
MAIN OUTCOME MEASURES: Bone turnover markers (BTMs), bone mineral density (BMD), fracture, and safety data are reported.
RESULTS: Reductions in BTMs were maintained (long-term) or achieved rapidly (crossover) after denosumab administration. In the long-term group, BMD further increased for cumulative 6-year gains of 15.2% (lumbar spine) and 7.5% (total hip). During the first 3 years of denosumab treatment, the crossover group had significant gains in lumbar spine (9.4%) and total hip (4.8%) BMD, similar to the long-term group during the 3-year FREEDOM trial. In the long-term group, fracture incidences remained low and below the rates projected for a virtual placebo cohort. In the crossover group, 3-year incidences of new vertebral and nonvertebral fractures were similar to those of the FREEDOM denosumab group. Incidence rates of adverse events did not increase over time. Six participants had events of osteonecrosis of the jaw confirmed by adjudication. One participant had a fracture adjudicated as consistent with atypical femoral fracture.
CONCLUSION: Denosumab treatment for 6 years remained well tolerated, maintained reduced bone turnover, and continued to increase BMD. Fracture incidence remained low.
Mots-clé
Aged, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Bone Density/drug effects, Cross-Over Studies, Female, Fractures, Bone/epidemiology, Fractures, Bone/prevention & control, Humans, Incidence, Middle Aged, Osteoporosis, Postmenopausal/drug therapy, Osteoporosis, Postmenopausal/epidemiology, Placebos, RANK Ligand/antagonists & inhibitors, Risk Factors, Time
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/01/2014 10:13
Dernière modification de la notice
09/05/2019 1:04
Données d'usage